Pfizer

MILWAUKEE – October 29, 2026 -- ManpowerGroup (NYSE: MAN) has elected Lidia Fonseca, Pfizer's former Executive Vice President and Chief Digital and Technology Officer, to its Board of Directors, effective November 1, 2026.

Fonseca built Pfizer's enterprise AI program from inception

Fonseca served as Pfizer's Chief Digital and Technology Officer from January 2019 to April 2026. She led the company's enterprise AI, digital, data and technology strategy, as well as Learning & Development and Business Process Excellence. She scaled the AI program across the enterprise, contributing to significant growth and cost savings.

She now serves as Senior Advisor to Pfizer's Chief Executive Officer and sits on the Board of Directors of Medtronic plc.

Delray Beach, Fla. – – October 08, 2026 -- The global Active Pharmaceutical Ingredients (API) market will grow from USD 149.02 billion in 2026 to USD 199.42 billion by 2031, a 6.0% compound annual growth rate, according to new data from MarketsandMarkets.

North America commands 43.1% of global API sales as domestic manufacturing investment accelerates

North America held the largest regional share of the API market in 2025 at 43.1%, driven by established pharmaceutical R&D infrastructure and rising investment in domestic production capacity. The US leads regional output in high-value and complex API development, supported by a dense base of pharmaceutical companies, contract manufacturing organizations, and specialized API producers.

Tokyo – October 07, 2026 -- Astellas Pharma Inc. (TSE: 4503) will present 21 abstracts from its oncology portfolio at the European Society for Medical Oncology Congress 2026, running October 23-27 in Madrid, Spain.

Enfortumab vedotin combination shows longest follow-up data yet in urothelial cancer

Presentations on PADCEV (enfortumab vedotin) plus pembrolizumab include the longest follow-up reported to date for patients with locally advanced or metastatic urothelial cancer, alongside subgroup and treatment-setting analyses. Additional data cover trials in progress evaluating bladder preservation strategies in muscle-invasive bladder cancer.

South San Francisco, Calif. – September 28, 2026 -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA) promoted Dr. Michael White from Chief Scientific Officer to President, Research and Development, effective September 28, 2026.

White expands authority over IDEAYA's oncology pipeline after five years as CSO

Dr. White has served as Chief Scientific Officer at IDEAYA since 2021, overseeing research into synthetic lethality and antibody-drug conjugate (ADC) programs targeting solid tumors. The precision medicine oncology company's pipeline spans multiple indications, including uveal melanoma, pancreatic cancer, small cell lung cancer, non-small cell lung cancer, colorectal cancer and breast cancer.

Pune, India – September 23, 2026 -- The global lupus nephritis market was valued at $1.96 billion in 2025 and is projected to reach $4.08 billion by 2034, expanding at a compound annual growth rate of 8.5% through the forecast period, according to a new analysis by Maximize Market Research.

North America leads treatment adoption on strong pharmaceutical research capabilities

North America holds the leading position in the market, supported by advanced healthcare infrastructure and higher awareness of autoimmune diseases. The United States drives regional demand through its established pharmaceutical industry and strong clinical research activity, while Canada contributes through its developed healthcare system focused on autoimmune disease management.

Plymouth Meeting, Pa. – September 18, 2026 -- The National Comprehensive Cancer Network (NCCN) Oncology Research Program has awarded funding for four quality improvement projects targeting metastatic prostate cancer (mPCA) care, backed by Pfizer Global Medical Grants (GMG).

Four institutions receive two-year grants to standardize mPCA treatment protocols

The selected projects, each set for completion within two years, will run at UT Southwestern Simmons Comprehensive Cancer Center, Georgetown University, Northwestern University's Robert H. Lurie Comprehensive Cancer Center, and Moffitt Cancer Center. Changchuan (Charles) Jiang, MD, at UT Southwestern will lead a biomarker action-loop initiative within a major U.S. safety-net cancer program. Paul Leger, MD, at Georgetown will implement multilevel interventions across the Medstar Health Network under the I-CARE PCA project.